Targeted Treatment Based on CtDNA Genotyping Combined with Tislelizumab and HAIC As Salvage Treatment for Advanced Colorectal Cancer Liver Metastasis Failed from Standard Systemic Treatment (SALVLIV Trial)
Hepatic arterial infuison chemothearpy (HAIC), targeted therapy, and programmed death-1 (PD-1) inhibitors have been demonstrated to be effective for colorectal cancer liver metastasis (CRCLM). Thus, the investigators will conduct a prospective trial to explore the efficacy and safety of targeted treatment based on ctDNA genotyping combined with tislelizumab and HAIC as salvage treatment for advanced CRCLM failed from standard systemic treatment, aiming to provide individualized optimized regimen for microsatellite stable (MSS) CRCLM in salvage treatment.
• 18-80 years old.
• Colorectal cancer confirmed by histopatology.
• The metastasis is mainly located in liver.
• Unresectable liver metastasis is confirmed by CT/MRI scan and multidisciplinary.
• Failed from standard first- and second-line systemic treatment.
• At least one measurable lesion according to modified Response Evaluation Criteria in Solid Tumors guidelines (mRECIST).
• Eastern Cooperative Oncology Group (ECOG) performance status \<2.
• Child-Pugh A or B (≤ 7).
• Expectant survival time ≥ 3 months.
⁃ Adequate organ function as follows:
∙ Hemoglobin ≥ 90 g/L;
‣ Absolute neutrophil count ≥ 1.5×10\^9/L;
‣ Blood platelet count ≥ 775×10\^9/L;
‣ Alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ 5 times of upper limit of normal (ULN);
‣ Total bilirubin ≤ 2 times of ULN;
‣ Serum creatinine ≤ 1.5 times of ULN;
‣ Albumin ≥ 30 g/L.
⁃ Patients sign informed consent.